Non-Covalent AKT1 Modulators for Isoform-Selective Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for modulating AKT1 and its mutants, such as AKT1 E17K, are inadequate in selectively targeting and inhibiting AKT1 activity over AKT2 and AKT3, particularly in the context of cancer therapy.
Innovation Solution
Development of specific compounds represented by Formulas (I) and (II) that can modulate AKT1 activity, including inhibiting AKT1 over AKT2 and AKT3, and their use in pharmaceutical compositions for treating cancers like breast, colorectal, and meningioma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to modulate AKT1, then AKT1 activity is inhibited, but selectivity over other AKT isoforms (AKT2, AKT3) is insufficient
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (Formula I and Formula II) that create localized interactions with AKT1's unique binding pocket. The compounds contain specific substituent patterns (R1, R2, R3, R4 groups and L linker) that form precise hydrogen bonds and hydrophobic interactions with AKT1 residues, providing selectivity for AKT1 over AKT2 and AKT3 isoforms.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the compounds including substituent types (halogen, alkyl, heterocycle), linker lengths (L1-L4), and core structures (Ring A, Ring B) to optimize binding affinity and selectivity for AKT1. These parameter adjustments enable differential binding to AKT1 compared to other isoforms.
2Reliability
If current treatments are used to modulate AKT1, then some AKT1 activity is suppressed, but effectiveness against AKT1 mutants (e.g., AKT1 E17K) is inadequate
Solution Approach 1:
The patent applies preliminary action by designing compounds that pre-adapt to bind to the mutant AKT1 E17K configuration. The molecular structure is optimized in advance to accommodate the glutamate-to-lysine substitution at position 17, forming complementary electrostatic interactions with the mutant residue before the mutant can activate downstream signaling pathways.
Solution Approach 2:
The patent uses parameter changes by modifying key molecular parameters including the charge distribution, hydrogen bonding capacity, and spatial arrangement of functional groups in Formulas I and II. These changes enable the compounds to maintain high binding affinity to both wild-type and mutant AKT1 isoforms, overcoming the resistance introduced by the E17K mutation.
3Reliability
If selective AKT1 inhibitors are developed, then AKT1-specific pathways are targeted, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: core aromatic rings (Ring A and Ring B), linker regions (L1-L4), and terminal substituent groups (R1-R4). This modular segmentation allows systematic optimization of each segment's contribution to AKT1 binding while maintaining overall molecular manageability and synthetic accessibility.
Solution Approach 2:
The patent employs universality by designing a core molecular scaffold (Formulas I and II) that serves multiple functions: providing structural rigidity, forming hydrogen bonds with AKT1, creating hydrophobic interactions, and accommodating various substituent variations. This universal scaffold can be systematically modified to target AKT1 with high precision while maintaining reasonable structural complexity.
Data Source
AI summary
Provided herein are non-covalent modifiers of AKT1 of Formula (I), (II), (II-A), (III), (III-A), (III-B), (IV), (IV-A), (IV-B), (V), (V-A), (V-B), (VI), (VI-A), or (VI-B), and pharmaceutical compositions thereof. In some embodiments, the present disclosure provides methods of modulating wild-type AKT1 using a compound or salt of Formula (I), (II), (II-A), (III), (III-A), (III-B), (IV), (IV-A), (IV-B), (V), (V-A), (V-B), (VI), (VI-A), or (VI-B), and pharmaceutical compositions thereof.